200 related articles for article (PubMed ID: 11673690)
21. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
[TBL] [Abstract][Full Text] [Related]
22. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Bonomi P
Lung Cancer; 2003 Aug; 41 Suppl 1():S43-8. PubMed ID: 12867061
[TBL] [Abstract][Full Text] [Related]
23. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
Ciardiello F; Caputo R; Borriello G; Del Bufalo D; Biroccio A; Zupi G; Bianco AR; Tortora G
Int J Cancer; 2002 Mar; 98(3):463-9. PubMed ID: 11920601
[TBL] [Abstract][Full Text] [Related]
24. ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
Herbst RS
Expert Opin Investig Drugs; 2002 Jun; 11(6):837-49. PubMed ID: 12036427
[TBL] [Abstract][Full Text] [Related]
25. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Janmaat ML; Giaccone G
Oncologist; 2003; 8(6):576-86. PubMed ID: 14657536
[TBL] [Abstract][Full Text] [Related]
26. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
27. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model.
Matsuo M; Sakurai H; Saiki I
Mol Cancer Ther; 2003 Jun; 2(6):557-61. PubMed ID: 12813135
[TBL] [Abstract][Full Text] [Related]
28. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
Koizumi F; Shimoyama T; Taguchi F; Saijo N; Nishio K
Int J Cancer; 2005 Aug; 116(1):36-44. PubMed ID: 15761868
[TBL] [Abstract][Full Text] [Related]
29. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
Tanno S; Ohsaki Y; Nakanishi K; Toyoshima E; Kikuchi K
Oncol Rep; 2004 Nov; 12(5):1053-7. PubMed ID: 15492792
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
31. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
Chan KC; Knox WF; Gee JM; Morris J; Nicholson RI; Potten CS; Bundred NJ
Cancer Res; 2002 Jan; 62(1):122-8. PubMed ID: 11782368
[TBL] [Abstract][Full Text] [Related]
32. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines.
Maddineni SB; Sangar VK; Hendry JH; Margison GP; Clarke NW
Br J Cancer; 2005 Jan; 92(1):125-30. PubMed ID: 15611794
[TBL] [Abstract][Full Text] [Related]
33. Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines.
Rosetti M; Tesei A; Ulivi P; Fabbri F; Vannini I; Brigliadori G; Granato AM; Amadori D; Zoli W
Cancer Biol Ther; 2005 Oct; 4(10):1089-95. PubMed ID: 16082196
[TBL] [Abstract][Full Text] [Related]
34. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
35. ZD1839 (Iressa): what's in it for the patient?
Natale RB; Zaretsky SL
Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785
[TBL] [Abstract][Full Text] [Related]
36. ZD1839 (Iressa): for more than just non-small cell lung cancer.
Ranson M
Oncologist; 2002; 7 Suppl 4():16-24. PubMed ID: 12202784
[TBL] [Abstract][Full Text] [Related]
37. EGFR inhibitors: clinical results.
De Marinis F; Nelli F; D'Auria G
Suppl Tumori; 2002; 1(6):S5-6. PubMed ID: 12658893
[No Abstract] [Full Text] [Related]
38. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
39. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
[TBL] [Abstract][Full Text] [Related]
40. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
Heimberger AB; Learn CA; Archer GE; McLendon RE; Chewning TA; Tuck FL; Pracyk JB; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2002 Nov; 8(11):3496-502. PubMed ID: 12429640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]